View Item 

Show simple item record

A systematic review of the safety of topical therapies for atopic dermatitis
dc.contributor.authorCallen, J.en_US
dc.contributor.authorChamlin, S.en_US
dc.contributor.authorEichenfield, Lawrence F.en_US
dc.contributor.authorEllis, C. N.en_US
dc.contributor.authorGirardi, M.en_US
dc.contributor.authorGoldfarb, Michael T.en_US
dc.contributor.authorHanifin, J.en_US
dc.contributor.authorLee, P.en_US
dc.contributor.authorMargolis, D.en_US
dc.contributor.authorPaller, A. S.en_US
dc.contributor.authorPiacquadio, Danielen_US
dc.contributor.authorPeterson, W.en_US
dc.contributor.authorKaulback, K.en_US
dc.contributor.authorFennerty, M.en_US
dc.contributor.authorWintroub, B. U.en_US
dc.date.accessioned2010-06-01T22:38:18Z
dc.date.available2010-06-01T22:38:18Z
dc.date.issued2007-02en_US
dc.identifier.citationCallen, J.; Chamlin, S.; Eichenfield, L.F.; Ellis, C.; Girardi, M.; Goldfarb, M.; Hanifin, J.; Lee, P.; Margolis, D.; Paller, A.S.; Piacquadio, D.; Peterson, W.; Kaulback, K.; Fennerty, M.; Wintroub, B.U. (2007). "A systematic review of the safety of topical therapies for atopic dermatitis." British Journal of Dermatology 156(2): 203-221. <http://hdl.handle.net/2027.42/75613>en_US
dc.identifier.issn0007-0963en_US
dc.identifier.issn1365-2133en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75613
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17223859&dopt=citationen_US
dc.format.extent209191 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 The Authors Journal Compilation 2007 British Association of Dermatologistsen_US
dc.subject.otherAtopic Dermatitisen_US
dc.subject.otherCalcineurin Inhibitorsen_US
dc.subject.otherSafetyen_US
dc.subject.otherSteroidsen_US
dc.titleA systematic review of the safety of topical therapies for atopic dermatitisen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum† Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, U.S.A.en_US
dc.contributor.affiliationother* Department of Dermatology, Northwestern University's Feinberg School of Medicine, Chicago, IL, U.S.A.en_US
dc.contributor.affiliationother† Department of Dermatology, University of California San Diego, San Diego, CA, U.S.A.en_US
dc.contributor.affiliationother§ Department of Dermatology, Yale University School of Medicine, New Haven, CT, U.S.A.en_US
dc.contributor.affiliationother¶ Department of Dermatology, Oregon Health and Science University, Portland, OR, U.S.A.en_US
dc.contributor.affiliationother** Departments of Dermatology and Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA, U.S.A.en_US
dc.contributor.affiliationother†† Department of Gastroenterology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, U.S.A.en_US
dc.contributor.affiliationother†† Medical Advisory Secretariat, Ministry of Health and Long Term Care, Toronto, ON, Canadaen_US
dc.contributor.affiliationother§§ Department of Dermatology, University of California San Francisco, 1701 Division Street, Room 338, San Francisco, CA 94143-0316, U.S.A.en_US
dc.identifier.pmid17223859en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75613/1/j.1365-2133.2006.07538.x.pdf
dc.identifier.doi10.1111/j.1365-2133.2006.07538.xen_US
dc.identifier.sourceBritish Journal of Dermatologyen_US
dc.identifier.citedreferenceLeung DYM, Bieber T. Atopic dermatitis. Lancet 2003; 361: 151 – 60.en_US
dc.identifier.citedreferenceSpergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112: S118 – 27.en_US
dc.identifier.citedreferenceWilliams HC. Atopic eczema – why we should look at the environment. BMJ 1995; 311: 1241 – 2.en_US
dc.identifier.citedreferenceWilliams HC. Atopic dermatitis. N Engl J Med 2005; 352: 2314 – 24.en_US
dc.identifier.citedreferenceHoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic dermatitis. Health Technol Assess 2000; 4: 1 – 191.en_US
dc.identifier.citedreferenceAshcroft DM, Dimmick P, Garside R et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ 2005; 330: 516 – 22.en_US
dc.identifier.citedreferenceBoner AL, Richelli C, De Stefano G et al. Adrenocortical function during prolonged treatment with clobetasone butyrate in children with chronic atopic dermatitis and elevated IgE levels. Int J Clin Pharmacol Res 1985; 5: 127 – 31.en_US
dc.identifier.citedreferenceAllen BR, Lakhanpaul M, Morris A et al. Systemic exposure, tolerability and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003; 88: 969 – 73.en_US
dc.identifier.citedreference9 Food and Drug Administration. Pediatric Advisory Committee. Briefing Information, 15 February 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm (accessed on 6 August 2006).en_US
dc.identifier.citedreferenceBieber T, Cork M, Ellis C et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005; 211: 77 – 8.en_US
dc.identifier.citedreferenceEllison JA, Patel L, Ray DW et al. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000; 105: 794 – 9.en_US
dc.identifier.citedreferenceJones SK, MacKie RM, Hole DJ, Gillis CR. Further evidence of the safety of tar in the management of psoriasis. Br J Dermatol 1985; 113: 97 – 101.en_US
dc.identifier.citedreferencePittelkow M, Perry H, Muller S et al. Skin cancer in patients with psoriasis treated with coal tar. Arch Dermatol 1981; 117: 465 – 8.en_US
dc.identifier.citedreferenceStern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998; 90: 1278 – 83.en_US
dc.identifier.citedreferenceStern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994; 73: 2759 – 64.en_US
dc.identifier.citedreferenceMaughan WZ, Muller SA, Perry HO et al. Incidence of skin cancers in patients with atopic dermatitis treated with coal tar. A 25-year follow-up study. J Am Acad Dermatol 1980; 3: 612 – 15.en_US
dc.identifier.citedreferenceDrake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczemous dermatitis. Doxepin Study Group. Arch Dermatol 1995; 131: 1403 – 8.en_US
dc.identifier.citedreferenceDrake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. J Am Acad Dermatol 1994; 31: 613 – 16.en_US
dc.identifier.citedreferenceFisher AA. The antihistamines. J Am Acad Dermatol 1980; 3: 303 – 6.en_US
dc.identifier.citedreferenceAngelini G. Topical drugs. In: Textbook of Contact Dermatitis ( Rycroft RJG, MennÉ T, Frosch PJ, eds ), 2nd edn. Berlin: Springer-Verlag, 1995; 490.en_US
dc.identifier.citedreferenceShelley WB, Shelley ED, Talanin NY. Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. J Am Acad Dermatol 1996; 34: 143 – 4.en_US
dc.identifier.citedreference22 Bioglan Pharma Package Insert – Zonalon (Doxepin Hydrochloride) Cream, 5%. Malvern, PA: 2002 (updated).en_US
dc.identifier.citedreferenceJappe U, Schnuch A, Uter W. Sensitization to antimicrobials in atopic eczema. Br J Dermatol 2003; 149: 87 – 93.en_US
dc.identifier.citedreference24 From Food and Drug Administration via Freedom of Information Act summary basis of approval for various topical antibiotics including erythromycin, clinidamycin, and topical antiseptics with agents such as chlohexidine, chloroxylenol etc. http://www.fda.gov.en_US
dc.identifier.citedreferenceAkers PA. Risks of unoccluded topical steroids in clinical trials. Arch Dermatol 1980; 116: 786 – 8.en_US
dc.identifier.citedreferenceBerth-Jones J, Damstra RJ, Golsch S et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomized, double-blind, parallel group study. BMJ 2003; 326: 1 – 6.en_US
dc.identifier.citedreferenceFriedlander F, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0·05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002; 46: 387 – 93.en_US
dc.identifier.citedreferenceFreeman S, Howard A, Foley P et al. Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0·05% lotion (Desowen ® ) vs. vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis. Australas J Dermatol 2002; 43: 186 – 9.en_US
dc.identifier.citedreferenceHanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147: 528 – 37.en_US
dc.identifier.citedreferenceKorting G. 0·25% Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0·1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol 1992; 42: 159 – 61.en_US
dc.identifier.citedreference31 From Food and Drug Administration via Freedom of Information Act summary basis of approval for various topical steroids including fluticasone propionate, clobetasol propionate etc. http://www.fda.gov.en_US
dc.identifier.citedreferenceMorren N, Dooms-Goossens D. Corticosteroid allergy in children: a potential complication of atopic eczema. Eur J Dermatol 1994; 4: 106 – 9.en_US
dc.identifier.citedreferenceWilkinson TA. Hydrocortisone sensitivity: clinical features of fifty-nine cases. J Am Acad Dermatol 1992; 27: 683 – 7.en_US
dc.identifier.citedreferenceAlani SD, Alani MD. Allergic contact dermatitis and conjunctivitis to corticosteroids. Contact Dermatitis 1976; 2: 301 – 4.en_US
dc.identifier.citedreferenceFoti C, Bonifazi E, Casulli C et al. Contact allergy to topical corticosteroids in children with atopic dermatitis. Contact Dermatitis 2005; 52: 162 – 3.en_US
dc.identifier.citedreferenceIngber A. What's new in contact dermatitis: allergy to topical steroids in Israeli patients with contact dermatitis. Isr Med Assoc J 2002; 4 ( Suppl. 11 ): 867.en_US
dc.identifier.citedreferenceBranco BA. Cutaneous corticosteroid therapy and cataract in man. J Toxicol Cutaneous Ocul Toxicol 2002; 21: 161 – 8.en_US
dc.identifier.citedreference38 From Food and Drug Administration via Freedom of Information Act summary basis of approval for various topical steroids including fluticasone propionate – topical dosage form, mometasone furoate – inhalation dosage form only. http://www.fda.gov.en_US
dc.identifier.citedreferenceReitamo S, Wollenberg A, Schopf E et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136: 999 – 1006.en_US
dc.identifier.citedreferenceBekersky I, Fitzsimmons W, Tanase A et al. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001; 44 ( Suppl. 1 ): S17 – 27.en_US
dc.identifier.citedreferenceKang S, Lucky AW, Pariser D et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44 ( Suppl. 1 ): S58 – 64.en_US
dc.identifier.citedreferencePaller A, Eichenfield LF, Leung DY et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44 ( Suppl. 1 ): S47 – 57.en_US
dc.identifier.citedreferenceSoter NA, Fleischer AB Jr, Webster GF et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II. Safety. J Am Acad Dermatol 2001; 44 ( Suppl. 1 ): S39 – 46.en_US
dc.identifier.citedreferenceEichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495 – 504.en_US
dc.identifier.citedreferenceWahn U, Bos JD, Goodfield M et al. Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2.en_US
dc.identifier.citedreferenceHo VC, Gupta A, Kaufmann R et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155 – 62.en_US
dc.identifier.citedreferenceFurue M, Terao H, Moroi Y et al. Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis. J Dermatol 2004; 31: 277 – 83.en_US
dc.identifier.citedreferenceKempers S, Boguniewicz M, Carter E et al. Investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0·03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51: 515 – 25.en_US
dc.identifier.citedreferenceLuger TA, Lahfa M, Folster-Holst R et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004; 15: 169 – 78.en_US
dc.identifier.citedreferenceMeurer M, Fartasch M, Albrecht G et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365 – 72.en_US
dc.identifier.citedreferenceNakahara T, Koga T, Fukagawa S et al. Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/emollient sequential therapy in patients with atopic dermatitis. J Dermatol 2004; 31: 524 – 8.en_US
dc.identifier.citedreferencePapp K, Staab D, Harper J et al. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. Int J Dermatol 2004; 43: 978 – 83.en_US
dc.identifier.citedreferenceWellington K, Noble S. Pimecrolimus: a review of its use in atopic dermatitis. Am J Clin Dermatol 2004; 5: 479 – 95.en_US
dc.identifier.citedreferenceHanifin JM, Paller AS, Eichenfield L et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53 ( 2 Suppl. 2 ): S186 – 94.en_US
dc.identifier.citedreferenceWolff K, Fleming C, Hanifin J et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 2005; 152: 1296 – 303.en_US
dc.identifier.citedreferenceFleischer AB, Ling M, Eichenfield L et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002; 47: 562 – 70.en_US
dc.identifier.citedreferenceReitamo S, Ortonne JP, Sand C et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0·1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152: 1282 – 9.en_US
dc.identifier.citedreferenceFood and Drug Administration. Alerts for Healthcare Professionals, March 2005. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/elidelHCP.htm and http://www.fda.gov/cder/drug/InfoSheets/HCP/ProtopicHCP.htm (accessed on 6 August 2006).en_US
dc.identifier.citedreferenceVeenhuis RT, van Horssen J, Bos RP et al. Highly increased urinary 1-hydroxypyrene excretion rate in patients with atopic dermatitis treated with topical coal tar. Arch Dermatol Res 2002; 294: 168 – 71.en_US
dc.identifier.citedreferenceTurpeinen M, Lehtokoski-Lehtiniemi E, Leisti S, Salo OP. Percutaneous absorption of hydrocortisone during and after the acute phase of dermatitis in children. Pediatr Dermatol 1988; 5: 276 – 9.en_US
dc.identifier.citedreferenceHehir M, Du Vivier A, Eilon L. Investigation of the pharmacokinetics of clobetasol propionate and clobetasone butyrate after a single application of ointment. Clin Exp Dermatol 1983; 8: 143 – 51.en_US
dc.identifier.citedreferenceMcGowan R, Tucker P, Joseph D et al. Short-term growth and bone turnover in children undergoing occlusive steroid (‘wet-wrap’) dressings for treatment of atopic eczema. J Dermatolog Treat 2003; 14: 149 – 52.en_US
dc.identifier.citedreferenceKristmundsdottir F, David TJ. Growth impairment in children with atopic eczema. J R Soc Med 1987; 80: 9 – 12.en_US
dc.identifier.citedreferenceWolthers OD, Heuck C, Ternowitz T et al. Insulin-like growth factor axis, bone and collagen turnover in children with atopic dermatitis treated with topical glucocorticosteroids. Dermatology 1996; 192: 337 – 42.en_US
dc.identifier.citedreferenceAalto-Korte K, Turpeinen M. Bone mineral density in patients with atopic dermatitis. Br J Dermatol 1997; 136: 172 – 5.en_US
dc.identifier.citedreferencePatel L, Clayton PE, Jenney ME et al. Adult height in patients with childhood onset atopic dermatitis. Arch Dis Child 1997; 76: 505 – 8.en_US
dc.identifier.citedreferencePatel L, Clayton PE, Addison GM et al. Linear growth in prepubertal children with atopic dermatitis. Arch Dis Child 1998; 79: 169 – 72.en_US
dc.identifier.citedreferenceHoetzenecker W, Meingassner JG, Ecker R et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673 – 84.en_US
dc.identifier.citedreferenceLesko MJ, Lever RS, MacKie RM, Parrott DM. The effect of topical steroid application on natural killer cell activity. Clin Exp Allergy 1989; 19: 633 – 6.en_US
dc.identifier.citedreferenceHarper J, Smith C, Rubins A et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005; 124: 695 – 9.en_US
dc.identifier.citedreferenceTandon V. Systemic Exposure of Topical Tacrolimus. Office of Clinical Pharmacology and Biopharmaceutics. Available at: http://www.fda.gov/ohrms/dockets/ac/00/slides/3659s1_05_Tandon/ (accessed on 6 August 2006).en_US
dc.identifier.citedreferenceAlaiti S, Kang S, Fiedler V et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998; 38: 69 – 76.en_US
dc.identifier.citedreferenceStiehm ER, Roberts RL, Kaplan MS et al. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol 2005; 53 ( 2 Suppl. 2 ): S206 – 13.en_US
dc.identifier.citedreferenceThaci D, Steinmeyer K, Ebelin ME et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology 2003; 207: 37 – 42.en_US
dc.identifier.citedreferenceLing M, Gottlieb A, Pariser D et al. Randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. J Dermatolog Treat 2005; 16: 142 – 8.en_US
dc.identifier.citedreferenceBillich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004; 269: 29 – 35.en_US
dc.identifier.citedreferencePapp K, Breuer K, Meurer M et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005; 52: 247 – 53.en_US
dc.identifier.citedreferenceFood and Drug Administration. Postmarketing Safety Review – PID D030565. Drugs: Topical Corticosteroids. Rockville, MD: FDA Memorandum, 2003. http://www.fda.gov.en_US
dc.identifier.citedreferenceDunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137 – 48.en_US
dc.identifier.citedreferenceFood and Drug Administration. February 15th Meeting, Labeling Information, and NDAs. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm (accessed on 6 August 2006).en_US
dc.identifier.citedreferenceNiwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003; 149: 960 – 7.en_US
dc.identifier.citedreferenceJiang H, Yamamoto S, Nishikawa K, Kato R. Anti-tumor-promoting action of FK506, a potent immunosuppressive agent. Carcinogenesis 1993; 14: 67 – 71.en_US
dc.identifier.citedreferenceYamamoto S, Jiang H, Kato R. Inhibition of anthralin-caused skin tumor promotion and interleukin-1 alpha production by potent immunosuppressant FK506. Cancer Lett 1994; 83: 185 – 9.en_US
dc.identifier.citedreferenceYokota K, Gill TJ, Shinozuka H. Effects of oral versus topical administration of cyclosporine on phorbol ester promotion of murine epidermal carcinogenesis. Cancer Res 1989; 49: 4586 – 90.en_US
dc.identifier.citedreferenceLubbe J, Sorg O. Tacrolimus ointment and skin carcinogenesis in the DMBA/TPA model in mice. Br J Dermatol 2004; 151: 1275 – 6.en_US
dc.identifier.citedreferenceDaniel D, Meyer-Morse N, Bergsland EK et al. Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 2003; 197: 1017 – 28.en_US
dc.identifier.citedreferenceSiegel CT, Schreiber K, Meredith SC et al. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med 2000; 191: 1945 – 56.en_US
dc.identifier.citedreferenceGirardi M, Glusac E, Filler RB et al. The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J Exp Med 2003; 198: 747 – 55.en_US
dc.identifier.citedreferencePeto J. Cancer epidemiology in the last century and the next decade. Nature 2001; 411: 390 – 5.en_US
dc.identifier.citedreferenceKim HK, Jin SY, Lee NS et al. Posttransplant primary cutaneous Ki-1 (CD30)+/CD56+ anaplastic large cell lymphoma. Arch Pathol Lab Med 2004; 128: e96 – 9.en_US
dc.identifier.citedreferenceThomsen K, Wantzin GL. Extracutaneous spreading with fatal outcome of mycosis fungoides in a patient treated with cyclosporin A: a word of caution. Dermatologica 1987; 174: 236 – 8.en_US
dc.identifier.citedreferenceCatterall MD, Addis BJ, Smith JL, Coode PE. SÉzary syndrome: transformation to a high grade T-cell lymphoma after treatment with cyclosporin A. Clin Exp Dermatol 1983; 8: 159 – 69.en_US
dc.identifier.citedreferenceMahe E, Descamps V, Grossin M et al. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003; 149: 170 – 3.en_US
dc.identifier.citedreferenceCorazza M, Zampino MR, Montanari A et al. Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology 2003; 206: 330 – 3.en_US
dc.identifier.citedreferenceKirby B, Owen CM, Blewitt RW, Yates VM. Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy. J Am Acad Dermatol 2002; 47 ( Suppl. 2 ): S165 – 7.en_US
dc.identifier.citedreferenceZackheim HS, Koo J, LeBoit PE et al. Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine. J Am Acad Dermatol 2002; 47: 155 – 7.en_US
dc.identifier.citedreferencePielop JA, Jones D, Duvic M. Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. Int J Dermatol 2001; 40: 505 – 11.en_US
dc.identifier.citedreferenceThomas M, Chandi SM, George S et al. SÉzary syndrome – unmasked by cyclosporine. Int J Dermatol 1998; 37: 957 – 8.en_US
dc.identifier.citedreferenceCooper DL, Braverman IM, Sarris AH et al. Cyclosporine treatment of refractory T-cell lymphomas. Cancer 1993; 71: 2335 – 41.en_US
dc.identifier.citedreferenceMcMullan DM, Radovaneevic B, Jackow CM et al. Cutaneous T-cell lymphoma in a cardiac transplant recipient. Tex Heart Inst J 2001; 28: 203 – 7.en_US
dc.identifier.citedreferenceJemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10 – 30.en_US
dc.identifier.citedreferenceMuller AM, Ihorst G, Mertelsmann R et al. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005; 84: 1 – 12.en_US
dc.identifier.citedreferenceCartwright RA, McKinney PA, O'Brien C et al. Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire. Leuk Res 1988; 12: 81 – 8.en_US
dc.identifier.citedreferenceBernard SM, Cartwright RA, Bird CC et al. Aetiologic factors in lymphoid malignancies: a case–control epidemiological study. Leuk Res 1984; 8: 681 – 9.en_US
dc.identifier.citedreferenceBernstein L, Ross RK. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case–control study in Los Angeles County. Cancer Res 1992; 52: S5510 – 15.en_US
dc.identifier.citedreferenceGrulich AE, Vajdic CM, Kaldor JM et al. Birth order, atopy, and risk of non-Hodgkin lymphoma. J Natl Cancer Inst 2005; 97: 587 – 94.en_US
dc.identifier.citedreferenceSoderberg KC, Hagmar L, Schwartzbaum J, Feychting M. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health 2004; 4: 51.en_US
dc.identifier.citedreferenceDoody MM, Linet MS, Glass AG et al. Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control 1992; 3: 449 – 56.en_US
dc.identifier.citedreferenceHagstromer L, Ye W, Nyren O et al. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol 2005; 141: 1123 – 7.en_US
dc.identifier.citedreferenceTurner MC, Chen Y, Krewski D et al. Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol 2005; 162: 212 – 21.en_US
dc.identifier.citedreferenceTalbot-Smith A, Fritschi L, Divitini ML et al. Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort. Am J Epidemiol 2003; 157: 606 – 12.en_US
dc.identifier.citedreferenceCastaing M, Youngson J, Zaridze D et al. Is the risk of lung cancer reduced among eczema patients ? Am J Epidemiol 2005; 162: 542 – 7.en_US
dc.identifier.citedreferenceWen W, Shu XO, Linet MS et al. Allergic disorders and the risk of childhood acute lymphoblastic leukemia (United States) Cancer Causes Control 2000; 11: 303 – 7.en_US
dc.identifier.citedreferenceAgnew KL, Ruchlemer R, Catovsky D et al. Cutaneous findings in chronic lymphocytic leukaemia. Br J Dermatol 2004; 150: 1129 – 35.en_US
dc.identifier.citedreferenceRosenbaum PF, Buck GM, Brecher ML. Allergy and infectious disease histories and the risk of childhood acute lymphoblastic leukaemia. Paediatr Perinat Epidemiol 2005; 19: 152 – 64.en_US
dc.identifier.citedreferenceSchuz J, Morgan G, Bohler E et al. Atopic disease and childhood acute lymphoblastic leukemia. Int J Cancer 2003; 105: 255 – 60.en_US
dc.identifier.citedreferenceSpector L, Groves F, DeStefano F et al. Medically recorded allergies and the risk of childhood acute lymphoblastic leukaemia. Eur J Cancer 2004; 40: 579 – 84.en_US
dc.identifier.citedreferenceHolly EA, Eberle CA, Bracci PM. Prior history of allergies and pancreatic cancer in the San Francisco Bay area. Am J Epidemiol 2003; 158: 432 – 41.en_US
dc.identifier.citedreferenceNegri E, Bosetti C, La VC et al. Allergy and other selected diseases and risk of colorectal cancer. Eur J Cancer 1999; 35: 1838 – 41.en_US
dc.identifier.citedreferenceSilverman DT, Schiffman M, Everhart J et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80: 1830 – 7.en_US
dc.identifier.citedreferenceYe W, Chow WH, Lagergren J et al. Risk of adenocarcinomas of the oesophagus and gastric cardia in patients hospitalized for asthma. Br J Cancer 2001; 85: 1317 – 21.en_US
dc.identifier.citedreferenceBrenner AV, Linet MS, Fine HA et al. History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer 2002; 99: 252 – 9.en_US
dc.identifier.citedreferenceSchwartzbaum J, Jonsson F, Ahlbom A et al. Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer 2003; 106: 423 – 8.en_US
dc.identifier.citedreferenceMilan T, Verkasalo PK, Kaprio J et al. Lifestyle differences in twin pairs discordant for basal cell carcinoma of the skin. Br J Dermatol 2003; 149: 115 – 23.en_US
dc.identifier.citedreferenceMing ME, Levy RM, Hoffstad OJ et al. Validity of patient self-reported history of skin cancer. Arch Dermatol 2004; 140: 730 – 5.en_US
dc.identifier.citedreferenceMontgomery SM, Ehlin AG, Sparen P et al. Childhood indicators of susceptibility to subsequent cervical cancer. Br J Cancer 2002; 87: 989 – 93.en_US
dc.identifier.citedreferenceBecker N, Deeg E, Nieters A. Population-based study of lymphoma in Germany: rationale, study design and first results. Leuk Res 2004; 28: 713 – 24.en_US
dc.identifier.citedreferenceBecker N, Deeg E, Rudiger T, Nieters A. Medical history and risk for lymphoma: results of a population-based case–control study in Germany. Eur J Cancer 2005; 41: 133 – 42.en_US
dc.identifier.citedreferenceBoffett P, Ye W, Boman G, Nyren O. Lung cancer risk in a population-based cohort of patients hospitalized for asthma in Sweden. Eur Respir J 2002; 19: 127 – 33.en_US
dc.identifier.citedreferenceBosetti C, Talamini R, Franceschi S et al. Allergy and the risk of selected digestive and laryngeal neoplasms. Eur J Cancer Prev 2004; 13: 173 – 6.en_US
dc.identifier.citedreferenceBriggs NC, Levine RS, Brann EA. Allergies and risk of non-Hodgkin's lymphoma by subtype. Cancer Epidemiol Biomarkers Prev 2002; 11: 401 – 7.en_US
dc.identifier.citedreferenceBroberg A, Augustsson A. Atopic dermatitis and melanocytic naevi. Br J Dermatol 2000; 142: 306 – 9.en_US
dc.identifier.citedreferenceHedderson MM, Malone KE, Daling JR, White E. Allergy and risk of breast cancer among young women (United States). Cancer Causes Control 2003; 14: 619 – 26.en_US
dc.identifier.citedreferenceJourdan-Da Silva N, Perel Y, Mechinaud F et al. Infectious diseases in the first year of life, perinatal characteristics and childhood acute leukaemia. Br J Cancer 2004; 90: 139 – 45.en_US
dc.identifier.citedreferenceKogevinas M, Zock JP, Alvaro T et al. Occupational exposure to immunologically active agents and risk for lymphoma. Cancer Epidemiol Biomarkers Prev 2004; 13: 1814 – 18.en_US
dc.identifier.citedreferenceLee WJ, Cantor KP, Berzofsky JA et al. Non-Hodgkin's lymphoma among asthmatics exposed to pesticides. Int J Cancer 2004; 111: 298 – 302.en_US
dc.identifier.citedreferenceMehrany K, el-Azhary RA, Bouwhuis SA, Pittelkow MR. Cutaneous T-cell lymphoma and atopy: is there an association ? Br J Dermatol 2003; 149: 1013 – 17.en_US
dc.identifier.citedreferenceMenegaux F, Olshan AF, Neglia JP et al. Day care, childhood infections, and risk of neuroblastoma. Am J Epidemiol 2004; 159: 843 – 51.en_US
dc.identifier.citedreferencePompei R, Lampis G, Ingianni A et al. Allergy and tumour outcome after primary cancer therapy. Int Arch Allergy Immunol 2004; 133: 174 – 8.en_US
dc.identifier.citedreferenceRohan P, Komenda S. Contribution to the coincidence of malignant tumours and some allergic manifestations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2002; 146: 95 – 8.en_US
dc.identifier.citedreferenceSantillan AA, Camargo CA Jr, Colditz GA. A meta-analysis of asthma and risk of lung cancer (United States). Cancer Causes Control 2003; 14: 327 – 34.en_US
dc.identifier.citedreferenceSchabath MB, Delclos GL, Martynowicz MM et al. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol 2005; 161: 412 – 22.en_US
dc.identifier.citedreferenceSynnerstad I, Nilsson L, Fredrikson M, Rosdahl I. Fewer melanocytic nevi found in children with active atopic dermatitis than in children without dermatitis. Arch Dermatol 2004; 140: 1471 – 5.en_US
dc.identifier.citedreferenceWong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003; 327: 794 – 8.en_US
dc.identifier.citedreferenceBoguniewicz M, Fiedler VC, Raimer S et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102: 637 – 44.en_US
dc.identifier.citedreferenceLan CC, Huang CC, Chen YT et al. Tacrolimus ointment for the treatment of atopic dermatitis: report of first clinical experience in Taiwan. Kaohsiung J Med Sci 2003; 19: 296 – 304.en_US
dc.identifier.citedreferenceWon CH, Seo PG, Park YM et al. A multicenter trial of the efficacy and safety of 0·03% tacrolimus ointment for atopic dermatitis in Korea. J Dermatolog Treat 2004; 15: 30 – 4.en_US
dc.identifier.citedreferenceFreeman AK, Serle J, van Veldhuisen P et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis 2004; 73: 267 – 71.en_US
dc.identifier.citedreferenceChapman MS, Schachner LA, Breneman D et al. Tacrolimus ontment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol 2005; 53 ( 2 Suppl. 2 ): S177 – 85.en_US
dc.identifier.citedreferenceKoo JY, Fleischer AB Jr, Abramovits W et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol 2005; 53 ( 2 Suppl. 2 ): S195 – 205.en_US
dc.identifier.citedreferenceReitamo S, Rustin M, Ruzicka T et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547 – 55.en_US
dc.identifier.citedreferenceReitamo S, Harper J, Bos JD et al. 0·03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150: 554 – 62.en_US
dc.identifier.citedreferenceTorok HM, Maas-Irslinger R, Slayton RM. Clocortolone pivalate cream 0·1% used concomitantly with tacrolimus ointment 0·1% in atopic dermatitis. Cutis 2003; 72: 161 – 6.en_US
dc.identifier.citedreferencePacor ML, Di Lorenzo G, Martinelli N et al. Tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clin Exp Allergy 2004; 34: 639 – 45.en_US
dc.identifier.citedreferencevan Leent EJ, Graber M, Thurston M et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805 – 9.en_US
dc.identifier.citedreferenceKaufmann R, Folster-Holst R, Hoger P et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004; 114: 1183 – 8.en_US
dc.identifier.citedreferenceLuger T, van Leent EJ, Graeber M et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788 – 94.en_US
dc.identifier.citedreferenceKapp A, Papp K, Bingham A et al. Reduction in Eczema with Elidel (Infants) Multicenter Investigator Study Group. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277 – 84.en_US
dc.identifier.citedreferencePapp KA, Werfel T, Folster-Holst R et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005; 52: 240 – 6.en_US
dc.identifier.citedreferencePaller AS, Lebwohl M, Fleischer AB et al. Tacrolimus Ointment Study Group. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005; 52: 810 – 22.en_US
dc.identifier.citedreferenceViglioglia P, Jones ML, Peets EA. Once-daily 0.1% mometasone furoate cream versus twice-daily 0·1% betamethasone valerate cream in the treatment of a variety of dermatoses. J Int Med Res 1990; 18: 460 – 7.en_US
dc.identifier.citedreferenceVernon HJ, Lane AT, Weston W. Comparison of mometasone furoate 0·1% cream and hydrocortisone 1·0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol 1991; 24: 603 – 7.en_US
dc.identifier.citedreferenceHoybye S, Balk Moller S, De Cunha Bang F et al. Continuous and intermittent treatment of atopic dermatitis in adults with mometasone furoate versus hydrocortisone 17-butyrate. Curr Ther Res Clin Exp 1991; 50: 67 – 72.en_US
dc.identifier.citedreferenceYawalkar SJ, Schwerzmann L. Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis. J Am Acad Dermatol 1991; 25: 1163 – 6.en_US
dc.identifier.citedreferenceGuzzo CA, Weiss JS, Mogavero HS et al. A review of two controlled multicenter trials comparing 0·05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses. J Am Acad Dermatol 1991; 25: 1179 – 83.en_US
dc.identifier.citedreferenceBrunner N, Yawalkar S. A double-blind, multicenter, parallel-group trial with 0·05% halobetasol propionate ointment versus 0·1% diflucortolone valerate ointment in patients with severe, chronic atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol 1991; 25: 1160 – 3.en_US
dc.identifier.citedreferenceDatz B, Yawalkar S. A double-blind, multicenter trial of 0·05% halobetasol propionate ointment and 0·05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol 1991; 25: 1157 – 60.en_US
dc.identifier.citedreferenceHerz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol 1991; 25: 1166 – 9.en_US
dc.identifier.citedreferenceHaneke E. The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid. J Dermatolog Treat 1992; 3 ( Suppl. 2 ): 13 – 15.en_US
dc.identifier.citedreferenceNilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992; 27: 29 – 34.en_US
dc.identifier.citedreferenceRajka G, Avrach W, Gartner L, Overgaard-Petersen H. Mometasone furoate 0·1% fatty cream once daily versus betamethasone valerate 0·1% cream twice daily in the treatment of patients with atopic and allergic contact dermatitis. Curr Ther Res Clin Exp 1993; 54: 23 – 9.en_US
dc.identifier.citedreferenceBleehen SS, Chu AC, Hamann I et al. Fluticasone propionate 0·05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol 1995; 133: 592 – 7.en_US
dc.identifier.citedreferenceKoopmans B, Lasthein AB, Mork NJ et al. Multicentre randomized double-blind study of Locoid Lipocream fatty cream twice daily versus Locoid Lipocream once daily and Locobase once daily. J Dermatolog Treat 1995; 6: 103 – 6.en_US
dc.identifier.citedreferenceJorizzo J, Levy M, Lucky A et al. Multicenter trial for long-term safety and efficacy comparison of 0·05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 1995; 33: 74 – 7.en_US
dc.identifier.citedreferenceLawlor F. Prednicarbate 0·25% ointment in the treatment of atopic dermatitis: a vehicle-controlled double-blind study. J Dermatolog Treat 1995; 6: 233 – 5.en_US
dc.identifier.citedreferenceAliaga A, Rodriguez M, Armijo M et al. Double-blind study of prednicarbate versus fluocortin butyl ester in atopic dermatitis. Int J Dermatol 1996; 35: 131 – 2.en_US
dc.identifier.citedreferenceSears HW, Bailer JW, Yeadon A. Efficacy and safety of hydrocortisone buteprate 0·1% cream in patients with atopic dermatitis. Clin Ther 1997; 19: 710 – 19.en_US
dc.identifier.citedreferenceTraulsen J. Hydrocortisone buteprate versus betamethasone valerate for once-daily treatment of atopic dermatitis. J Dermatolog Treat 1997; 8: 109 – 14.en_US
dc.identifier.citedreferenceMaloney JM, Morman MR, Stewart DM et al. Clobetasol propionate emollient 0·05% in the treatment of atopic dermatitis. Int J Dermatol 1998; 37: 142 – 4.en_US
dc.identifier.citedreferenceHanifin JM, Hebert AA, Mays SR et al. Effects of a low-potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. Curr Ther Res Clin Exp 1998; 59: 227 – 33.en_US
dc.identifier.citedreferenceWolkerstorfer A, Strobos MA, Glazenburg EJ et al. Fluticasone propionate 0·05% cream once daily versus clobetasone butyrate 0·05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol 1998; 39: 226 – 31.en_US
dc.identifier.citedreferencevan der Meer JB, Glazenburg EJ, Mulder PGH et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol 1999; 140: 1114 – 21.en_US
dc.identifier.citedreferenceFaergemann J, Christensen O, Sjovall P et al. An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2000; 14: 393 – 6.en_US
dc.identifier.citedreferencePei AYS, Chan HHL, Ho KM. The effectiveness of wet wrap dressings using 0·1% mometasone furoate and 0·005% fluticasone propionate ointments in the treatment of moderate to severe atopic dermatitis in children. Pediatr Dermatol 2001; 18: 343 – 8.en_US
dc.identifier.citedreferenceCato A, Swinehart JM, Griffin EI et al. Azone enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis. Int J Dermatol 2001; 40: 232 – 6.en_US
dc.identifier.citedreferenceChunharas A, Wisuthsarewong W, Wananukul S, Viravan S. Therapeutic efficacy and safety of loratadine syrup in childhood atopic dermatitis treated with mometasone furoate 0·1 per cent cream. J Med Assoc Thailand 2002; 85: 482 – 7.en_US
dc.identifier.citedreferenceTan M-H, Meador SL, Singer G, Lebwohl MG. An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0·005%, in patients with atopic dermatitis of the face and intertriginous areas. Int J Dermatol 2002; 41: 804 – 9.en_US
dc.identifier.citedreferencePrado de Oliveira ZN, Cuce LC, Arnone CA. Comparative evaluation of efficacy, tolerability and safety of 0·1% topical momethasone furoate and 0·05% desonide in the treatment of childhood atopic dermatitis. An Bras Dermatol 2002; 77: 25 – 33.en_US
dc.identifier.citedreferenceThomas KS, Armstrong S, Avery A et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ 2002; 324: 768.en_US
dc.identifier.citedreferenceKawashima M, Tango T, Noguchi T et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003; 148: 1212 – 21.en_US
dc.identifier.citedreferenceKirkup ME, Birchall NM, Weinberg EG et al. Acute and maintenance treatment of atopic dermatitis in children – two comparative studies with fluticasone propionate (0·05%) cream. J Dermatolog Treat 2003; 14: 141 – 8.en_US
dc.identifier.citedreferenceKantor I, Milbauer J, Posner M et al. Efficacy and safety of emollients as adjunctive agents in topical corticosteroid therapy for atopic dermatitis. Today's Ther Trends 1993; 11: 157 – 66.en_US
dc.identifier.citedreferenceGip L, Lindberg L, Nordin P et al. Clinical study of mometasone furoate cream 0·1% compared to hydrocortisone butyrate cream 0·1% in treatment of atopic and seborrheic dermatitis. Today's Ther Trends 1990; 8: 21 – 34.en_US
dc.identifier.citedreferenceCarpenter CL, Jolly HW, McCormick GE et al. Combined steroid-antiinfective topical therapy in common dermatoses: a double-blind, multi-center study of iodochlorhydroxyquin-hydrocortisone in 277 patients. Curr Ther Res Clin Exp 1973; 15: 650 – 9.en_US
dc.identifier.citedreferenceLaurberg G. Topical treatment with urea-hydrocortisone in atopic dermatitis. A controlled study against betamethasone 17-valerate. Dermatologica 1975; 151: 30 – 3.en_US
dc.identifier.citedreferenceWachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976; 95: 323 – 8.en_US
dc.identifier.citedreferenceFattah AA, el-Shiemy S, Faris R, Tadros SS. A comparative clinical evaluation of a new topical steroid ‘halcinonide’ and hydrocortisone in steroid-responsive dermatoses. J Int Med Res 1976; 4: 228 – 31.en_US
dc.identifier.citedreferenceel-Hefnawi H, el-Shiemy S, Paris R, Tadros SS. Double-blind paired comparison clinical trial of halcinonide and hydrocortisone. Cutis 1978; 22: 97 – 9.en_US
dc.identifier.citedreferenceHjorth N, Schmidt H, Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica 1985; 4: 126 – 31.en_US
dc.identifier.citedreferenceAbdel Aal H, Abdallah MA, Iskandar IO, Salama NR. Clinical experience with 0·05% halometasone/1% triclosan cream in the treatment of acute infected and infection-prone eczema in Egypt. J Int Med Res 1987; 15: 383 – 90.en_US
dc.identifier.citedreferenceKorting HC, Zienicke H, Braun-Falco O et al. Modern topical glucocorticoids and anti-infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination ? Infection 1994; 22: 390 – 4.en_US
dc.identifier.citedreferencePoyner TF, Dass BK. Comparative efficacy and tolerability of fusidic acid/hydrocortisone cream (Fucidin TM H cream) and miconazole/hydrocortisone cream (Daktacort TM cream) in infected eczema. J Eur Acad Dermatol Venereol 1996; 7 ( Suppl. 1 ): S23 – 9.en_US
dc.identifier.citedreferenceRamsay CA, Savoie JM, Gilbert M et al. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol 1996; 7 ( Suppl. 1 ): S15 – 22.en_US
dc.identifier.citedreferenceHagstromer L, Nyren M, Emtestam L. Do urea and sodium chloride together increase the efficacy of moisturisers for atopic dermatitis skin? A comparative, double-blind and randomised study. Skin Pharmacol Appl Skin Physiol 2001; 14: 27 – 33.en_US
dc.identifier.citedreferenceLoden M, Andersson A-C, Lindberg M. The effect of two urea-containing creams on dry, eczematous skin in atopic patients: II. Adverse effects. J Dermatolog Treat 1999; 10: 171 – 5.en_US
dc.identifier.citedreferenceLoden M, Andersson A-C, Anderson C et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. Acta Derm Venereol (Stockh) 2002; 82: 45 – 7.en_US
dc.identifier.citedreferenceJemec GBE, Osterlind D. Cancer in patients treated with coal tar: a long-term follow up study. J Eur Acad Dermatol Venereol 1994; 3: 1153 – 6.en_US
dc.identifier.citedreferenceDrake LA, Cohen L, Gillies R et al. Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis. J Am Acad Dermatol 1999; 41: 209 – 14.en_US
dc.identifier.citedreferenceBerberian BJ, Breneman DL, Drake LA et al. The addition of topical doxepin to corticosteroid therapy: an improved treatment regimen for atopic dermatitis. Int J Dermatol 1999; 38: 145 – 8.en_US
dc.identifier.citedreferenceLever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988; 119: 189 – 98.en_US
dc.identifier.citedreferenceBreneman DL, Hanifin JM, Berge CA et al. The effect of antibacterial soap with 1·5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis 2000; 66: 296 – 300.en_US
dc.identifier.citedreferenceRavenscroft JC, Layton AM, Eady EA et al. Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (Fus R ) Staphylococcus aureus in atopic eczema. Br J Dermatol 2003; 148: 1010 – 17.en_US
dc.identifier.citedreferenceHarper J. Double-blind comparison of an antiseptic oil-based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. Round Table Ser – R Soc Med 1995; 37: 42 – 7.en_US
dc.identifier.citedreferenceBelloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair), in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol 2005; 15: 31 – 6.en_US
dc.identifier.citedreferenceHaider SA. Treatment of atopic eczema in children: clinical trial of 10% sodium cromoglycate ointment. BMJ 1977; i: 1570 – 2.en_US
dc.identifier.citedreferenceKjellman NI, Gustafsson IM. Topical sodium cromoglycate in atopic dermatitis. A disappointing but informative trial. Allergy 1986; 41: 423 – 8.en_US
dc.identifier.citedreferenceStainer R, Matthews S, Arshad SH et al. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2–12 years: a double-blind, randomized, placebo-controlled trial. Br J Dermatol 2005; 152: 334 – 41.en_US
dc.identifier.citedreferenceStucker M, Pieck C, Stoerb C et al. Topical vitamin B 12 – a new therapeutic approach in atopic dermatitis – evaluation of efficacy and tolerability in a randomized placebo-controlled multicentre clinical trial. Br J Dermatol 2004; 150: 977 – 83.en_US
dc.identifier.citedreferencede Prost Y, Bodemer C, Teillac D. Randomised double-blind placebo-controlled trial of local cyclosporin in atopic dermatitis. Acta Derm Venereol (Stockh) 1989; 144 ( Suppl. ): 136 – 8.en_US
dc.identifier.citedreferenceHanifin JM, Chan SC, Cheng JB et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107: 51 – 6.en_US
dc.identifier.citedreferenceGriffiths CE, van Leent EG, Gilbert M, Traulsen J. Cipamfylline Study Group. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol 2002; 147: 299 – 307.en_US
dc.identifier.citedreferenceHiroi J, Sengoku T, Morita K et al. Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice. Jpn J Pharmacol 1998; 76: 175 – 83.en_US
dc.identifier.citedreferenceMarsella R, Nicklin CF, Saglio S, Lopez J. Investigation on the clinical efficacy and safety of 0·1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. Vet Dermatol 2004; 15: 294 – 303.en_US
dc.identifier.citedreferenceBensignor E, Olivry T. Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. Vet Dermatol 2005; 16: 52 – 60.en_US
dc.identifier.citedreferenceSmitt JHS, Winterberg DH, Oosting J. Treatment of atopic dermatitis with topical corticosteroids in children. Efficacy and systemic effects of triamcinolone acetonide and alclometasone dipropionate. Eur J Dermatol 1993; 3: 549 – 52.en_US
dc.identifier.citedreferencePatel L, Clayton PE, Addison GM et al. Adrenal function following topical steroid treatment in children with atopic dermatitis. Br J Dermatol 1995; 132: 950 – 5.en_US
dc.identifier.citedreferenceWolkerstorfer A, Visser RL, de Waard-van der Spek FB et al. Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution. Br J Dermatol 2000; 143: 999 – 1004.en_US
dc.identifier.citedreferenceCrespi HG. Topical corticosteroid therapy for children: alclometasone dipropionate cream 0·05% Clin Ther 1986; 8: 203 – 10.en_US
dc.identifier.citedreferenceLucky AW, Grote GD, Williams JL et al. Effect of desonide ointment, 0·05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis 1997; 59: 151 – 3.en_US
dc.identifier.citedreferenceHanifin JM. The role of topical steroids in the treatment of allergic skin disease. In: Towards Evolution of Allergic Skin Disease Management Hong Kong: Excerpta Medica, 1996; 1 – 2.en_US
dc.identifier.citedreferenceMoshang T. Prednicarbate emollient cream 0·1% in pediatric patients with atopic dermatitis. Cutis 2001; 68: 63 – 9.en_US
dc.identifier.citedreferencePaller AS, Nimmagadda S, Schachner L et al. Fluocinolone acetonide 0·01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. J Am Acad Dermatol 2003; 48: 569 – 77.en_US
dc.identifier.citedreferenceRuzicka T, Bieber T, Schopf E et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337: 816 – 21.en_US
dc.identifier.citedreferencePatel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol 2003; 139: 1184 – 6.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2133.2006.07538.x.pdf
Size:
204.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.